Biokey

Executive Summary

Biokey is a Chinese diagnostics company specializing in innovative testing solutions for infectious diseases and genetic applications. Leveraging next-generation sequencing (NGS) and digital PCR technologies, the company offers precise and comprehensive diagnostic panels targeting both clinical and research markets. Founded in 2010 and now in the commercial stage with 200-500 employees, Biokey has established itself as a player in China's rapidly growing precision diagnostics sector. Its focus on high-demand areas such as infectious disease and genomics positions it to benefit from increasing healthcare spending and the shift toward personalized medicine, particularly in the post-pandemic landscape where advanced diagnostic tools are essential for pathogen surveillance and genetic screening. The company's competitive advantage lies in its dual-technology platform (NGS and digital PCR), enabling accurate detection across a range of applications. As China's diagnostics market expands, driven by government initiatives to enhance disease prevention and genetic testing accessibility, Biokey is well-positioned to capture market share. However, competition from established local and international players remains a challenge. The company's ability to secure regulatory approvals, form strategic partnerships, and commercialize new products will be key to sustaining growth. With a solid foundation and a targeted product pipeline, Biokey demonstrates moderate upside potential for investors seeking exposure to the Chinese diagnostics space.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval for a novel infectious disease panel70% success
• Q1 2027Launch of a digital PCR-based liquid biopsy test60% success
• Q2 2026Strategic partnership with a major hospital network for NGS-based pathogen detection80% success